Surgery or Radiotherapy for Primary and Oligometastatic Lung Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 151
Special Issue Editor
Special Issue Information
Dear Colleagues,
This Special Issue will focus on the management of lung cancer through different perspectives. In the past, the treatment decision was often easy: surgery for early lung cancer, radio-chemotherapy for locally advanced disease and a systemic treatment for metastatic disease. The progress made in different disciplines has led to a more sophisticated approach questioning the role and position of surgery or radiotherapy for early lung cancer but also in case of more advanced tumors. Surgery has evolved to a less invasive procedure with the introduction of video-assisted thoracic surgery, leading to a rapid recovery procedure and lower toxicities. In the area of radiotherapy, the technique has evolved to more precise targeting of the tumors with the introduction of intensity-modulated radiotherapy (IMRT), stereotactic ablative radiotherapy (SBRT) and adaptive radiotherapy, stereotactic body radiotherapy and on- line imaging procedures.
Systemic treatment has seen major breakthroughs with the introduction of molecular targeted therapy (TKis) and immune-checkpoint inhibitor monoclonal antibodies (the anti PD-1/PD-L1 compounds). This has not only improved the response rate but has also achieved long-term survival. Experimental data have also demonstrated some synergistic effects with local radiation. Trials suggested a real benefit to adding a local modality to this systemic treatment, especially for oligo metastatic disease. Questions are numerous: surgery or radiotherapy, the type of surgery or radiotherapy, the patient selection and the optimal timing, and so on.
The type of radiotherapy and surgery are also now more often discussed for the management of early lung cancer. The population aging, facing the issue of co-morbidity; moreover, screening programs have allowed more very early lung tumors to be found. Should we still apply our old approach or should we adapt our treatments?
In this Special Issue, colleagues from different disciplines will present their point of view on those issues outlining the progress, new approaches, area of research and possibilities for the future.
Prof. Dr. Paul Jules van Houtte
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
